Prevalence of Metabolic Syndrome in Iranian Adults Receiving Antiretroviral Treatment for HIV.

IF 0.8 4区医学 Q4 IMMUNOLOGY

Current HIV Research Pub Date : 2025-02-11 DOI:10.2174/011570162X340090250204072449

Hamid Khazdooz, Ladan Abbasian, Nooshin Shirzad, Pouria Khashayar, SeyedAhmad SeyedAlinaghi, Mahsa Malekahmadi, Mahboobeh Hemmatabadi

{"title":"Prevalence of Metabolic Syndrome in Iranian Adults Receiving Antiretroviral Treatment for HIV.","authors":"Hamid Khazdooz, Ladan Abbasian, Nooshin Shirzad, Pouria Khashayar, SeyedAhmad SeyedAlinaghi, Mahsa Malekahmadi, Mahboobeh Hemmatabadi","doi":"10.2174/011570162X340090250204072449","DOIUrl":null,"url":null,"abstract":"Background: The increased risk of metabolic syndrome (MetS) and its subcomponents among people living with HIV/AIDS, especially in developing countries, is well documented with the global pooled prevalence of the related risk factors in this population.Objective: This study aimed to explore the prevalence of MetS among Iranian People living with HIV according to the ATP III and Iranian criteria.Methods: The cross-sectional study was conducted on consecutive patients who visited THE re-ferral centre for AIDS/HIV between May to December 2023. A total of 130 participants (n=83; 63.8% male) were investigated based on the inclusion criteria, which included having a minimum age of 25 and a maximum of 65 years and following a stable ART treatment regimen for at least six months. A Chi-square test was used to determine the relationship between the categorical variables. Uni/Multi-variable linear regression analysis was used to quantify the associations be-tween MetS and HIV by the independent variables.Results: The incidence of MetS according to ATP III and Iranian criteria were 42 (32.3%) and 45 (34.6%), which was higher in older patients (p=0.001) and those with more duration since HIV diagnosis (p=0.02). Around 33.1% and 16.1% were overweight and obese, respectively. Among the components of MetS, the highest prevalence (50.8%) was related to low HDL, and the lowest was related to fasting blood sugar (21.5%). The average body fat mass, protein mass, Soft lean mass, and percentage body fat were 18.54±9.46 kg, 10.91±2.17 kg, 51.31±9.61 kg, and 24.86±10.25% that were higher in MetS group (p<0.05).Conclusion: Our study points out the high prevalence of MetS in an Iranian population living with HIV, especially those suffering from the underlying disease for a longer time. Conducting multi-centric studies with larger sample sizes is needed to confirm our results and determine the most effective measures.","PeriodicalId":10911,"journal":{"name":"Current HIV Research","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current HIV Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/011570162X340090250204072449","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The increased risk of metabolic syndrome (MetS) and its subcomponents among people living with HIV/AIDS, especially in developing countries, is well documented with the global pooled prevalence of the related risk factors in this population.

Objective: This study aimed to explore the prevalence of MetS among Iranian People living with HIV according to the ATP III and Iranian criteria.

Methods: The cross-sectional study was conducted on consecutive patients who visited THE re-ferral centre for AIDS/HIV between May to December 2023. A total of 130 participants (n=83; 63.8% male) were investigated based on the inclusion criteria, which included having a minimum age of 25 and a maximum of 65 years and following a stable ART treatment regimen for at least six months. A Chi-square test was used to determine the relationship between the categorical variables. Uni/Multi-variable linear regression analysis was used to quantify the associations be-tween MetS and HIV by the independent variables.

Results: The incidence of MetS according to ATP III and Iranian criteria were 42 (32.3%) and 45 (34.6%), which was higher in older patients (p=0.001) and those with more duration since HIV diagnosis (p=0.02). Around 33.1% and 16.1% were overweight and obese, respectively. Among the components of MetS, the highest prevalence (50.8%) was related to low HDL, and the lowest was related to fasting blood sugar (21.5%). The average body fat mass, protein mass, Soft lean mass, and percentage body fat were 18.54±9.46 kg, 10.91±2.17 kg, 51.31±9.61 kg, and 24.86±10.25% that were higher in MetS group (p<0.05).

Conclusion: Our study points out the high prevalence of MetS in an Iranian population living with HIV, especially those suffering from the underlying disease for a longer time. Conducting multi-centric studies with larger sample sizes is needed to confirm our results and determine the most effective measures.

查看原文本刊更多论文

接受抗逆转录病毒治疗的伊朗成人中代谢综合征的患病率

背景：在艾滋病毒/艾滋病感染者中，特别是在发展中国家，代谢综合征（MetS）及其亚成分的风险增加，这一现象在全球范围内的相关危险因素的普遍存在中得到了充分的记录。目的：本研究旨在根据ATP III和伊朗标准探讨伊朗HIV感染者中MetS的流行情况。方法：对2023年5月至12月在The AIDS/HIV转诊中心连续就诊的患者进行横断面研究。共130名参与者(n=83；63.8%男性)根据纳入标准进行调查，纳入标准包括最低年龄为25岁，最高年龄为65岁，接受稳定的ART治疗方案至少6个月。采用卡方检验确定分类变量之间的关系。采用单变量/多变量线性回归分析，通过自变量量化MetS与HIV之间的相关性。结果：根据ATP III和伊朗标准，MetS的发生率分别为42（32.3%）和45(34.6%)，其中老年患者（p=0.001）和HIV诊断后持续时间较长的患者（p=0.02）较高。超重和肥胖的比例分别为33.1%和16.1%。在MetS的组成部分中，发病率最高（50.8%）与低HDL有关，最低与空腹血糖有关（21.5%）。平均体脂质量、蛋白质质量、软瘦质量和体脂百分比分别为18.54±9.46 kg、10.91±2.17 kg、51.31±9.61 kg和24.86±10.25%，met组较高(p结论：本研究指出伊朗HIV感染者中MetS的患病率较高，特别是那些长期患有基础疾病的人群。需要进行更大样本量的多中心研究来确认我们的结果并确定最有效的措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current HIV Research 医学-病毒学

CiteScore

1.90

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Current HIV Research covers all the latest and outstanding developments of HIV research by publishing original research, review articles and guest edited thematic issues. The novel pioneering work in the basic and clinical fields on all areas of HIV research covers: virus replication and gene expression, HIV assembly, virus-cell interaction, viral pathogenesis, epidemiology and transmission, anti-retroviral therapy and adherence, drug discovery, the latest developments in HIV/AIDS vaccines and animal models, mechanisms and interactions with AIDS related diseases, social and public health issues related to HIV disease, and prevention of viral infection. Periodically, the journal invites guest editors to devote an issue on a particular area of HIV research of great interest that increases our understanding of the virus and its complex interaction with the host.